Case Characteristics, Clinical Data, And Outcomes of Hospitalized COVID-19 Patients In Qom Province, Iran: A Prospective Cohort Study
Pourhoseingholi et al.,
Case Characteristics, Clinical Data, And Outcomes of Hospitalized COVID-19 Patients In Qom Province, Iran: A..,
Research Square, doi:10.21203/rs.3.rs-365321/v2 (Preprint)
Prospective study of 2,468 hospitalized COVID-19 patients in Iran, showing higher mortality with aspirin treatment. IR.MUQ.REC.1399.013.
risk of death, 32.0% higher, HR 1.32, p = 0.04, treatment 71 of 290 (24.5%), control 268 of 2,178 (12.3%), adjusted per study, multivariable, Cox proportional hazards.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Pourhoseingholi et al., 26 May 2021, prospective, Iran, preprint, mean age 57.9, 11 authors, study period 2 February, 2020 - 20 July, 2020, average treatment delay 7.4 days.
Abstract: Case Characteristics, Clinical Data, And Outcomes of
Hospitalized COVID-19 Patients In Qom Province, Iran: A
Prospective Cohort Study
Mohamad Amin Pourhoseingholi
Shahid Beheshti University of Medical Sciences
Hosein Yousefi
Qom University of Medical Science and Health Services
Hassan Fatemi Manesh
Qom University of Medical Science and Health Services
Nima Najafian Motahaver
Qom University of Medical Science and Health Services
Zahra Heydari
Qom University of Medical Science and Health Services
Mehdi Azizmohammad Looha
Shahid Beheshti University of Medical Sciences
Nazanin Taraghikhah
Shahid Beheshti University of Medical Sciences
Maryam Yazdi
Qom University of Medical Science and Health Services
Zahra Salami
Qom University of Medical Science and Health Services
Elmira Moallemi
Qom University of Medical Science and Health Services
Seyed Hasan Adeli ( adeli@muq.ac.ir )
Qom University of Medical Science and Health Services
Research Article
Keywords: COVID-19, Pandemic, Iran, Risk factor, Cohort
Posted Date: May 26th, 2021
DOI: https://doi.org/10.21203/rs.3.rs-365321/v2
License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full
License
Page 1/25
Abstract
The outbreak of severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) dates back to December 2019 in
China. Iran has been one of the most virus inflicted countries. The aim of this study was to report demographics,
signs and symptoms, laboratory findings, therapeutic approaches, and outcomes. This observational cohort study
was performed from 20th February 2020 to 20th July 2020. Patients’ information was recorded in their medical files.
Multivariable analysis was performed to assess demographics, signs and symptoms, paraclinical data, treatments,
outcomes of disease, and finding the risk factors of death subject to COVID-19. Of all 2468 participants, the mean
age was 57.9±17.6 years and 56.8% of patients were male. The most significant comorbidities were seen among
those who have Hypertension and Diabetes Mellitus. 14.42% were admitted to ICU, and 17.2% died in hospital. The
significant risk factors of death were ageing, male gender, HTN, CHF, CVA, CKD, increasing ESR, PT, WBC, liver
function tests, and decreasing Oxygen saturation. Incontinent results in the case of COVID-19 outcomes and deathrelated risk factors attribute to marked differences in demographics and health care systems. The patients with
hazardous risk factors must be detected urgently and monitored closely to save more lives.
Late treatment
is less effective
pourhoseingholi
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit